Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (98) clinical trials

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate Gonadotropin-Releasing Hormone Analog and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

PRIMARY OBJECTIVES: I. To evaluate the effect of neoadjuvant androgen receptor antagonist ARN-509 (apalutamide) with or without abiraterone acetate, GnRH agonist, and prednisone on the feasibility of performing nerve-sparing radical prostatectomy (RP) in men with high-risk prostate cancer (PCa). OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM ...


PSMA PET Imaging of Recurrent Prostate Cancer

The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.


Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk Resectable Localized or Locally Advanced Prostate Cancer

PRIMARY OBJECTIVES: I. Safety and tolerability of therapy with the study drugs in men with high-risk localized prostate cancer. SECONDARY OBJECTIVES: I. To assess the proportion of patients who achieve pathological complete response (CR) with the study drugs in men with high-risk localized prostate cancer. EXPLORATORY OBJECTIVES: I. To study ...


Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

PRIMARY OBJECTIVES: I. To evaluate the safety of pembrolizumab in combination with pTVG-HP (pTVG-HP plasmid DNA vaccine) in patients with castration-resistant, metastatic prostate cancer. II. To determine the 6-month progression-free survival and median time to radiographic progression in patients with castration-resistant metastatic prostate cancer treated with pembrolizumab in combination with ...


Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

PRIMARY OBJECTIVES: I. To evaluate gallium Ga 68-labeled PSMA-11 PET whole body imaging for detection of disease recurrence in clinically relevant anatomic regions. OUTLINE Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV). Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging. After completion of study, patients ...

Phase N/A

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

PRIMARY OBJECTIVES: I. To evaluate the incidence of genitourinary (GU) and gastrointestinal (GI) acute and late toxicity for patients treated with prostate stereotactic body radiotherapy (SBRT) with simultaneous integrative boost, urethral ring sparing, and enhanced prostate localization (magnetic resonance imaging [MRI\-computed tomography [CT] fusion). II. To also evaluate the incidence ...

Phase N/A

Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy

The present study evaluates the feasibility of postoperative stereotactic hypofractionated external beam radiation therapy delivered in patients who underwent radical prostatectomy with adverse pathological features or early biochemical failure. Regardless the two settings (adjuvant or salvage), external beam radiation therapy for prostate cancer is usually a protracted course, since a ...


Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

PRIMARY OBJECTIVES: I. Determine if a 1-year low-fat fish oil (omega-3 fatty acid) supplemented diet results in decreased prostate cancer Decipher score as compared to a control group in men on active surveillance. SECONDARY OBJECTIVES: I. Evaluate the effect of a low-fat (LF)/fish oil (FO) intervention on prostate biopsy tissue ...

Phase N/A

CyberKnife as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free Survival (bDFS), using Phoenix and American Society of Therapeutic Radiation and Oncology (ASTRO) definitions, at 5 years. During the ...

Phase N/A

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

PRIMARY OBJECTIVES: I. To assess the proportion of patients with biochemical recurrent prostate cancer (BCR-PC) treated with phenelzine (phenelzine sulfate) who achieve a prostate-specific antigen (PSA) decline of >= 50% from baseline. SECONDARY OBJECTIVES: I. To monitor potential toxicities and/or beneficial effects on quality of life of phenelzine in prostate ...